FDA Cites Par Health USA, LLC & Endo USA, Inc. in 2026-04-15 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
FDA issued a Warning Letter to Par Health USA, LLC & Endo USA, Inc. on 2026-04-15 citing: CGMP/Finished Pharmaceuticals/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/par-health-usa-llc-endo-usa-inc-722121-04152026
Argus analysis
Par Health USA, LLC & Endo USA, Inc. (MARCS-CMS 722121, FEI 1818977) received an FDA Warning Letter dated April 15, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: CGMP/Finished Pharmaceuticals/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on April 21, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Par Health USA, LLC & Endo USA, Inc. MARCS-CMS 722121 — April 15, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-68 Product: Drugs Recipient: Recipient Name Mr. John Caldwell Recipient Title VP Manufacturing Operations Par Health USA, LLC & Endo USA, Inc. 870 Parkdale Road Rochester , MI 48307-1740 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-68 April 15, 2026 Dear Mr. Caldwell: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, ENDO USA, Inc., FEI 1818977, at 870 Parkdale Road, Rochester, from October 6 to 20, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your November 10, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)). Inadequate Design of Facility and Equipment Your firm is a contract manufacturer of sterile injectable drug products produced primarily through aseptic processing including, but not limited to, products for (b)(4) use. (b)(4) of your aseptic processing lines are described as “ (b)(4) restricted access barrier systems.” However, (b)(4) of these processing lines (b)(4) are not restricted access barrier systems (RABS). They lacked fundamental RABS design elements, such as (b)(4) , that are essential for reducing or eliminating direct gowned personnel intervention into the critical (ISO 5) area during batch manufacturing. (b)(4) are (b)(4) foundational elements of RABS design and control, minimizing contamination risk from the surrounding cleanroom environment. Without these basic features, your processing lines (b)(4) cannot be categorized as RABS. Additionally, your processing lines (b)(4) were designed as traditional aseptic filling lines surrounded by barrier (b)(4) under (b)(4) high efficiency particulate air (HEPA) systems. These processing lines required manually intensive operations during equipment setup and throughout routine production, and did not provide appropriate separation and protection of the ISO 5 areas. For exam…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Par Health USA, LLC & Endo USA, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Par Health USA, LLC & Endo USA, Inc. as of 2026-04-21. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Par Health USA, LLC & Endo USA, Inc. in 2026-04-15 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-par-health-usa-llc-and-endo-usa-inc-2026-04-15-cgmp
"FDA Cites Par Health USA, LLC & Endo USA, Inc. in 2026-04-15 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-par-health-usa-llc-and-endo-usa-inc-2026-04-15-cgmp.
Argus HQ Research. "FDA Cites Par Health USA, LLC & Endo USA, Inc. in 2026-04-15 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-par-health-usa-llc-and-endo-usa-inc-2026-04-15-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_par_health_usa_llc_and_endo_usa_inc_2026_04_15_cgmp_2026,
title = {FDA Cites Par Health USA, LLC & Endo USA, Inc. in 2026-04-15 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-par-health-usa-llc-and-endo-usa-inc-2026-04-15-cgmp},
note = {Accessed: July 13, 2026}
}